NASDAQ:IOBT IO Biotech (IOBT) Stock Price, News & Analysis $0.84 -0.05 (-5.59%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.80▼$0.9050-Day Range$0.84▼$1.6452-Week Range$0.80▼$2.10Volume635,287 shsAverage Volume150,213 shsMarket Capitalization$55.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get IO Biotech alerts: Email Address IO Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside926.9% Upside$8.67 Price TargetShort InterestHealthy0.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 11 Articles This WeekInsider TradingSelling Shares$68,524 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.21) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector462nd out of 910 stocksPharmaceutical Preparations Industry214th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIO Biotech has only been the subject of 3 research reports in the past 90 days.Read more about IO Biotech's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.17% of the float of IO Biotech has been sold short.Short Interest Ratio / Days to CoverIO Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IO Biotech has recently increased by 56.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIO Biotech does not currently pay a dividend.Dividend GrowthIO Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IOBT. Previous Next 2.3 News and Social Media Coverage News SentimentIO Biotech has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for IO Biotech this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IOBT on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat Follows3 people have added IO Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IO Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $68,524.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of IO Biotech is held by insiders.Percentage Held by Institutions54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IO Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IO Biotech are expected to decrease in the coming year, from ($1.21) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IO Biotech is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IO Biotech is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIO Biotech has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about IO Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About IO Biotech Stock (NASDAQ:IOBT)IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Read More IOBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOBT Stock News HeadlinesSeptember 5 at 4:49 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)September 5 at 2:43 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for IO Biotech (NASDAQ:IOBT)September 7, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.September 4 at 3:52 AM | americanbankingnews.comIO Biotech (NASDAQ:IOBT) Given "Overweight" Rating at Piper SandlerSeptember 4 at 2:37 AM | americanbankingnews.comMorgan Stanley Cuts IO Biotech (NASDAQ:IOBT) Price Target to $4.00September 3, 2024 | markets.businessinsider.comOptimistic Outlook on IO Biotech’s PFS Improvements Despite ORR SetbackSeptember 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for IO Biotech Amid Positive Phase 3 Trial Progress and Historical DataAugust 31, 2024 | markets.businessinsider.comIO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDASeptember 7, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.August 30, 2024 | globenewswire.comIO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaAugust 26, 2024 | globenewswire.comIO Biotech Announces Participation in Upcoming Investor ConferencesAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed on IO Biotech Amid Positive Phase 3 Study Prospects and Strong Financial FootingAugust 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)August 14, 2024 | msn.comThis 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics StockAugust 13, 2024 | globenewswire.comIO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsAugust 12, 2024 | 247wallst.com3 Penny Stocks with 190% Growth Potential According to Wall Street AnalystsAugust 9, 2024 | marketwatch.comIovance Biotherapeutics Shares Rise 27% After 2Q Revenue BeatJuly 25, 2024 | markets.businessinsider.comIO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024See More Headlines Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IOBT CUSIPN/A CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$12.00 Low Stock Price Target$4.00 Potential Upside/Downside+926.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.05% Return on Assets-62.54% Debt Debt-to-Equity RatioN/A Current Ratio7.84 Quick Ratio7.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book0.58Miscellaneous Outstanding Shares65,881,000Free Float64,366,000Market Cap$55.60 million OptionableNot Optionable Beta0.50 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Mai-Britt Zocca Ph.D. (Age 56)Founder, President, CEO, Principal Financial Officer & Director Comp: $892.24kMr. Devin Whittemore Smith (Age 56)Secretary, General Counsel & Chief Compliance Officer Comp: $621.8kDr. Qasim Iftikhar Ahmad M.D. (Age 53)Chief Medical Officer Comp: $503.28kProf. Inge Marie Svane M.D.Ph.D., Founder & Clinical AdvisorProf. Mads Hald Andersen M.D.Ph.D., Founder & Scientific AdvisorAnders LjungqvistFounderProf. Per Thor StratenFounderMs. Amy B. Sullivan M.B.A. (Age 53)Chief Financial Officer Comp: $391.24kMr. Eric Faulkner M.B.A.Chief Technical OfficerMr. Daniel G. Mannix Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsDURECTNASDAQ:DRRXVincerx PharmaNASDAQ:VINCaTyr PharmaNASDAQ:LIFENektar TherapeuticsNASDAQ:NKTRESSA PharmaNASDAQ:EPIXView All CompetitorsInsiders & InstitutionsNovo Holdings A SSold 658,809 shares on 8/20/2024Ownership: 6.723%Armistice Capital LLCSold 179,000 shares on 8/15/2024Ownership: 2.345%XTX Topco LtdBought 10,688 shares on 8/12/2024Ownership: 0.040%Renaissance Technologies LLCBought 13,600 shares on 8/9/2024Ownership: 0.274%Holdings A/S NovoSold 51,522 sharesTotal: $68,524.26 ($1.33/share)View All Insider TransactionsView All Institutional Transactions IOBT Stock Analysis - Frequently Asked Questions How have IOBT shares performed this year? IO Biotech's stock was trading at $1.88 at the start of the year. Since then, IOBT shares have decreased by 55.1% and is now trading at $0.8440. View the best growth stocks for 2024 here. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.04. When did IO Biotech IPO? IO Biotech (IOBT) raised $111 million in an initial public offering (IPO) on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share. Who are IO Biotech's major shareholders? IO Biotech's top institutional shareholders include Novo Holdings A S (6.72%), Armistice Capital LLC (2.35%), Renaissance Technologies LLC (0.27%) and XTX Topco Ltd (0.04%). Insiders that own company stock include Holdings A/S Novo, Vivo Capital Ix, Llc, Amy Sullivan and Brian Burkavage. View institutional ownership trends. How do I buy shares of IO Biotech? Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOBT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
